Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli Lilly
Eli Lilly’s weight loss drug, Zepbound, has been shown to lead to more significant weight loss than Novo Nordisk’s Wegovy, according to results from a new clinical trial. The study, funded by Lilly, is the first to compare the two drugs directly, providing valuable insights into their efficacy for weight loss. Lilly announced the results on Wednesday, claiming that Zepbound outperforms Wegovy, which has been a leader in the weight loss market.
Zepbound Shows Superior Weight Loss Results
The study, which involved 751 adults from across the U.S. and Puerto Rico, found that those who received Zepbound lost an average of 20.2% of their body weight, or about 50.3 pounds, after 72 weeks. In comparison, patients on Wegovy lost an average of 13.7% of their body weight, or 33.1 pounds. This difference in weight loss amounts to a 47% greater reduction in body weight for those taking Zepbound, according to Lilly.
Dr. Susan Spratt, an endocrinologist and senior medical director at Duke Health, commented on the results, acknowledging the effectiveness of both drugs despite Zepbound’s superior performance. «The amount of weight loss with both is astounding,» Dr. Spratt said, in an NBC report.
These results are part of a randomized, controlled clinical trial that examined the impact of both drugs on patients with obesity or those who were overweight. The study focused on the highest doses of either Zepbound or Wegovy and was conducted over the course of 72 weeks.
What does the drug do and how does it work?
Zepbound and Wegovy
Read more on economictimes.indiatimes.com
